S. Green

发表

A randomized controlled trial of intravenous montelukast in acute asthma.

C. Camargo, H. Smithline, M. Malice, 2003, American journal of respiratory and critical care medicine.

An Oral Selective M3 Anticholinergic Receptor Antagonist in COPD

S. Green, T. Reiss, C. Tozzi, 2006 .

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma.

R. Chapela, L. Fabbri, C. Camargo, 2010, The Journal of allergy and clinical immunology.

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

S. Green, C. Pinto, P. Mudd, 2019, European urology.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

S. Green, K. Jordan, B. Rapoport, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.

C. Zwaan, S. Green, Arlene F Taylor, 2015, The Lancet. Oncology.

ASTHMA Increase in urinary leukotriene LTE 4 levels in acute asthma : correlation with airflow limitation

M. Malice, S. Green, T. Reiss, 2004 .

Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation

M. Malice, S. Green, T. Reiss, 2004, Thorax.

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

A. Kimball, S. Green, M. Gooderham, 2018, The British journal of dermatology.

An oral selective M3 cholinergic receptor antagonist in COPD

S. Green, T. Reiss, C. Tozzi, 2006, European Respiratory Journal.

Aprepitant for the prevention of chemotherapy‐induced nausea and vomiting in paediatric subjects: An analysis by age group

C. Zwaan, S. Green, A. Pong, 2018, Pediatric blood & cancer.

Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

S. Green, M. Gooderham, K. Papp, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

A. Kimball, S. Green, K. Papp, 2017, The Lancet.

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups

I. Pavord, S. Birring, J. Smith, 2022, Lung.

Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)

I. Pavord, S. Birring, J. Smith, 2020 .

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

M. Struthers, R. Berger, C. Moyes, 2016, Journal of medicinal chemistry.

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

S. Green, T. Reiss, Haiyuan Zhu, 2010, The Journal of urology.

Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.

S. Green, T. Reiss, Achilles Alon, 2006, The Journal of urology.

Aprepitant for paediatric chemotherapy-induced nausea and vomiting - Authors' reply.

C. Zwaan, S. Green, H. Kang, 2015, The Lancet Oncology.

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

S. Green, A. Pong, K. Jordan, 2018 .

A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma.

S. Green, A. Becker, S. Smugar, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.

S. Green, D. Muccino, 2019, Pulmonary pharmacology & therapeutics.

Exploration of the heterogeneity of moderately emetogenic chemotherapy on response to fosaprepitant in a randomized phase 3 trial

S. Green, K. Jordan, B. Rapoport, 2016 .

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

I. Pavord, S. Birring, J. Smith, 2022, The Lancet.

Variability of urodynamic parameters in patients with overactive bladder

R. Railkar, S. Green, J. Palcza, 2011, Neurourology and urodynamics.

Comprehensive serum cytokine analysis identi ﬁ es IL-1RA and soluble IL-2R α as predictors of event-free survival in T-cell lymphoma

S. Green, K. Jordan, B. Rapoport, 2015 .

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

S. Green, A. Pong, K. Jordan, 2018, Supportive Care in Cancer.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

S. Green, K. Jordan, B. Rapoport, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in children.

C. Zwaan, S. Green, S. Loftus, 2014 .

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

A. Kimball, S. Green, K. Papp, 2017, The Lancet.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.